Related Experiment Video
Updated: Aug 20, 2026
Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
Danburstotug, an anti-PD-L1 antibody, in relapsed/refractory extra-nodal natural killer/T-cell lymphoma: The phase 2
Won Seog Kim1, Seok Jin Kim1, Jae-Cheol Jo2
1Division of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Abstract:
Relapsed/refractory extra-nodal natural killer/T-cell lymphoma (R/R ENKTL) has limited treatment options. Danburstotug, an antibody targeting programmed death-ligand 1 (PD-L1), was evaluated in adults with R/R ENKTL in a phase 2, open-label study (NCT04414163). Danburstotug 20 mg/kg was administered intravenously every 2 weeks up to 52 cycles, disease progression or unacceptable toxicity. In the full analysis set (n = 19), objective response rate (ORR; primary end-point) was 78.9% (95% confidence interval 54.4-94.0); complete response (CR) rate was 63.2% (38.4-83.7); 76.9% of participants maintained responses; and 90.9% of participants maintained CR for 2 years. In the intention-to-treat population (n = 23), median progression-free survival (PFS) was 29.4 months (12.0-46.9; 2-year PFS rate 62.1%); and median overall survival was 40.2 months (25.1-55.4; 2-year overall survival rate 77.9%). Treatment-emergent adverse events occurred in 91.3% of 23 participants (73/83 events were grade 1/2); grade 3 serious treatment-related adverse events comprised liver injury and uveitis (one participant each). High PD-L1 membrane specificity (MS) was associated with greater ORR, CR rate and PFS versus low PD-L1 MS. In tumour immune microenvironment assessments, clinical benefit was observed across immune tolerance and immune evasion subtypes, despite lower PD-L1 expression in immune evasion-B. Danburstotug demonstrated robust, durable efficacy and manageable safety. PD-L1 MS showed potential as a predictive biomarker.
Insights
Danburstotug shows promising results for relapsed/refractory extra-nodal natural killer/T-cell lymphoma (R/R ENKTL). This antibody targeting programmed death-ligand 1 (PD-L1) demonstrated durable responses and manageable safety in a phase 2 study.
Area of Science:
- Oncology
- Immunotherapy
- Hematology
Background:
- Relapsed/refractory extra-nodal natural killer/T-cell lymphoma (R/R ENKTL) presents limited therapeutic avenues.
- Programmed death-ligand 1 (PD-L1) is a key target in immuno-oncology.
Purpose of the Study:
- To evaluate the efficacy and safety of Danburstotug, a PD-L1 targeting antibody, in adults with R/R ENKTL.
- To explore the potential of PD-L1 membrane specificity (MS) as a predictive biomarker.
Main Methods:
- A phase 2, open-label study (NCT04414163) administered Danburstotug intravenously every 2 weeks.
- The study assessed objective response rate (ORR), complete response (CR) rate, progression-free survival (PFS), and overall survival.
- Treatment-emergent adverse events and PD-L1 MS were analyzed.
Main Results:
- The ORR was 78.9% and the CR rate was 63.2% in the full analysis set (n=19).
- Median PFS was 29.4 months and median overall survival was 40.2 months in the intention-to-treat population (n=23).
- High PD-L1 MS correlated with improved ORR, CR rate, and PFS. Treatment-related adverse events were generally manageable.
Conclusions:
- Danburstotug demonstrated robust and durable efficacy with a manageable safety profile in R/R ENKTL.
- PD-L1 MS emerged as a potential predictive biomarker for treatment response.
- The findings support Danburstotug as a viable therapeutic option for R/R ENKTL.
